Photoaging Photoaging, Laxity
Conditions
Interventions
Participants randomized to the botulinum toxin group will receive botulinum toxin type A (CCUG 7968 strain) injections for the treatment of crows feet at a dose of 10 units per side.,Participants rand
Botulinum toxin type A injection,Topical dihydromyricetin-containing serum,Combination treatment
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
All
Age
30 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Male or female participants aged 30to 45 years. 2. Presence of moderate or greater crows feet wrinkles, as assessed using the Merz 5 Point Crows Feet Scale. 3. Thai individuals of Asian ethnicity with Fitzpatrick skin types III to V.
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding women. 2. Participants with neuromuscular disorders, such as amyotrophic lateral sclerosis (ALS), myopathies, myasthenia gravis, or any other condition deemed unsafe by the investigator. 3. History of hypersensitivity or allergy to dihydromyricetin and/or botulinum toxin. 4. Use of oral isotretinoin or topical retinoids within 6 months prior to study enrollment. 5. History of botulinum toxin injection, dermal filler injection, platelet-rich plasma (PRP) injection, chemical peeling, skin tightening procedures, laser treatment, or thread lifting of the face within 6 months prior to study enrollment. 6. Use of oral or topical whitening agents, or oral antioxidant supplements within 3 months prior to study enrollment. 7. History of platelet disorders, coagulation abnormalities, anemia, liver disease, malignancy, autoimmune disorders, diabetes mellitus, or use of antiplatelet or anticoagulant medications, as well as any medical condition considered by the investigator to pose a safety risk (e.g., epilepsy). 8. Current smokers or individuals with a history of excessive alcohol consumption. 9. History of hypertrophic scars or keloids. 10. Presence of other dermatologic conditions in the treatment area, including skin infections or active dermatitis. 11. Diagnosed psychiatric disorders confirmed by a psychiatrist. 12. Refusal to undergo photography for treatment evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Merz 5-point scale for crow's feet Baseline, 1, 2, 3, 4, 5 and 6 months after treatment Blinded physician assessment,Safety 1, 2, 3, 4, 5 and 6 months after treatment Adverse events | — |
Secondary
| Measure | Time frame |
|---|---|
| Participants improvement scale 1, 2, 3, 4, 5 and 6 months after treatment Quartile scale,Skin quality Baseline, 1, 2, 3, 4, 5 and 6 months after treatment Antera 3D | — |
Countries
Thailand
Contacts
Public ContactRungsima Wanitphakdeedecha
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed